Taurine upregulated 1: Prognostic biomarker in breast cancer

Abstract

The most common kind of cancer and the second leading cause of cancer mortality in women is breast cancer (BC). The most proven cause of mortality in BC patients comprises tumor metastasis and invasive development. Long noncoding RNAs are endangered by a number of crucial mechanisms involved in BC metastasis (lncRNAs). RNAs that are classified as lncRNAs are thought to be longer than 200 nucleotides in length. Literature has long shown that lncRNAs are promising therapeutic targets in BC as well as diagnostic and prognostic indicators. Only a few studies have, to our knowledge, described the bioenergetics of taurine upregulated 1 (TUG1). Human cancer has been linked to a new lncRNA called TUG1. TUG1 has drawn increasing interest in recent years and has been shown to express abnormally in several forms of cancer. Numerous research suggested that the development of tumefaction and cell metabolism may be favorably correlated with TUG1. As a result, we aimed to concentrate on recent developments in the primary molecular processes of TUG1 in cancer in this review. This includes its role in drug resistance, invasion, cell migration, apoptosis, and proliferation. Most recent investigations asserted that TUG was overexpressed in BC tissues and cell lines as compared to their normal counterparts. In order to better understand the critical impact of tamoxifen (TMX) resistance and improve quality of life (QOL), researchers are looking for an early diagnostic marker.

Keywords

• breast cancer
• long noncoding rnas
• taurine upregulated 1
• tamoxifen
• resistance